nodes	percent_of_prediction	percent_of_DWPC	metapath
Olopatadine—S100A2—exocrine gland—esophageal cancer	0.0387	0.116	CbGeAlD
Olopatadine—S100A1—exocrine gland—esophageal cancer	0.0356	0.106	CbGeAlD
Olopatadine—S100A1—neck—esophageal cancer	0.0228	0.0681	CbGeAlD
Olopatadine—S100A13—neck—esophageal cancer	0.0202	0.0604	CbGeAlD
Olopatadine—S100A2—epithelium—esophageal cancer	0.0168	0.0503	CbGeAlD
Olopatadine—S100A2—bronchus—esophageal cancer	0.0166	0.0495	CbGeAlD
Olopatadine—Corneal disorder—Capecitabine—esophageal cancer	0.0153	0.0965	CcSEcCtD
Olopatadine—S100A1—bronchus—esophageal cancer	0.0153	0.0456	CbGeAlD
Olopatadine—S100A2—trachea—esophageal cancer	0.0149	0.0445	CbGeAlD
Olopatadine—S100A13—epithelium—esophageal cancer	0.0137	0.0411	CbGeAlD
Olopatadine—S100A1—trachea—esophageal cancer	0.0137	0.041	CbGeAlD
Olopatadine—S100A12—epithelium—esophageal cancer	0.0136	0.0405	CbGeAlD
Olopatadine—S100A13—smooth muscle tissue—esophageal cancer	0.0132	0.0396	CbGeAlD
Olopatadine—S100A1—digestive system—esophageal cancer	0.0118	0.0352	CbGeAlD
Olopatadine—S100A2—lung—esophageal cancer	0.0107	0.032	CbGeAlD
Olopatadine—S100A13—digestive system—esophageal cancer	0.0105	0.0313	CbGeAlD
Olopatadine—S100A12—digestive system—esophageal cancer	0.0103	0.0308	CbGeAlD
Olopatadine—White blood cell disorder—Capecitabine—esophageal cancer	0.0102	0.0641	CcSEcCtD
Olopatadine—S100A13—lung—esophageal cancer	0.00874	0.0261	CbGeAlD
Olopatadine—S100A12—lung—esophageal cancer	0.00862	0.0258	CbGeAlD
Olopatadine—Punctate keratitis—Capecitabine—esophageal cancer	0.00699	0.044	CcSEcCtD
Olopatadine—S100A1—lymph node—esophageal cancer	0.00673	0.0201	CbGeAlD
Olopatadine—S100A13—lymph node—esophageal cancer	0.00597	0.0179	CbGeAlD
Olopatadine—S100A12—lymph node—esophageal cancer	0.00589	0.0176	CbGeAlD
Olopatadine—S100B—lymph node—esophageal cancer	0.00582	0.0174	CbGeAlD
Olopatadine—Ocular discomfort—Methotrexate—esophageal cancer	0.00579	0.0365	CcSEcCtD
Olopatadine—Swelling face—Capecitabine—esophageal cancer	0.00371	0.0234	CcSEcCtD
Olopatadine—Visual acuity reduced—Capecitabine—esophageal cancer	0.00297	0.0187	CcSEcCtD
Olopatadine—Infection—Carboplatin—esophageal cancer	0.0029	0.0182	CcSEcCtD
Olopatadine—HRH1—epithelium—esophageal cancer	0.00275	0.00821	CbGeAlD
Olopatadine—Keratitis—Capecitabine—esophageal cancer	0.00272	0.0171	CcSEcCtD
Olopatadine—HRH1—smooth muscle tissue—esophageal cancer	0.00265	0.00791	CbGeAlD
Olopatadine—Pharyngolaryngeal pain—Capecitabine—esophageal cancer	0.00262	0.0165	CcSEcCtD
Olopatadine—Laryngeal pain—Capecitabine—esophageal cancer	0.00259	0.0163	CcSEcCtD
Olopatadine—Ulcer—Cisplatin—esophageal cancer	0.00253	0.0159	CcSEcCtD
Olopatadine—Pain—Carboplatin—esophageal cancer	0.00249	0.0157	CcSEcCtD
Olopatadine—HRH1—trachea—esophageal cancer	0.00243	0.00726	CbGeAlD
Olopatadine—Body temperature increased—Carboplatin—esophageal cancer	0.0023	0.0145	CcSEcCtD
Olopatadine—HRH1—digestive system—esophageal cancer	0.00209	0.00624	CbGeAlD
Olopatadine—Eye irritation—Capecitabine—esophageal cancer	0.00207	0.013	CcSEcCtD
Olopatadine—Oropharyngeal pain—Capecitabine—esophageal cancer	0.00194	0.0122	CcSEcCtD
Olopatadine—Lacrimation increased—Capecitabine—esophageal cancer	0.00192	0.0121	CcSEcCtD
Olopatadine—Ulcer—Capecitabine—esophageal cancer	0.00187	0.0118	CcSEcCtD
Olopatadine—HRH1—lung—esophageal cancer	0.00174	0.00521	CbGeAlD
Olopatadine—Dry eye—Capecitabine—esophageal cancer	0.00163	0.0103	CcSEcCtD
Olopatadine—CYP3A4—digestive system—esophageal cancer	0.00162	0.00483	CbGeAlD
Olopatadine—Nasopharyngitis—Cisplatin—esophageal cancer	0.00156	0.00979	CcSEcCtD
Olopatadine—Eye pain—Capecitabine—esophageal cancer	0.00142	0.00894	CcSEcCtD
Olopatadine—Ulcer—Methotrexate—esophageal cancer	0.00139	0.00875	CcSEcCtD
Olopatadine—Thirst—Capecitabine—esophageal cancer	0.00135	0.00848	CcSEcCtD
Olopatadine—Conjunctivitis—Cisplatin—esophageal cancer	0.0013	0.0082	CcSEcCtD
Olopatadine—HRH1—lymph node—esophageal cancer	0.00119	0.00357	CbGeAlD
Olopatadine—Dry skin—Capecitabine—esophageal cancer	0.00118	0.0074	CcSEcCtD
Olopatadine—Visual impairment—Cisplatin—esophageal cancer	0.00116	0.0073	CcSEcCtD
Olopatadine—Nasopharyngitis—Capecitabine—esophageal cancer	0.00115	0.00722	CcSEcCtD
Olopatadine—Eye disorder—Cisplatin—esophageal cancer	0.00112	0.00708	CcSEcCtD
Olopatadine—Influenza—Capecitabine—esophageal cancer	0.00111	0.00698	CcSEcCtD
Olopatadine—Immune system disorder—Cisplatin—esophageal cancer	0.00109	0.00684	CcSEcCtD
Olopatadine—Mediastinal disorder—Cisplatin—esophageal cancer	0.00108	0.00683	CcSEcCtD
Olopatadine—Erythema—Cisplatin—esophageal cancer	0.00105	0.00659	CcSEcCtD
Olopatadine—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.00103	0.00648	CcSEcCtD
Olopatadine—Weight increased—Capecitabine—esophageal cancer	0.00101	0.00635	CcSEcCtD
Olopatadine—Visual disturbance—Methotrexate—esophageal cancer	0.00101	0.00634	CcSEcCtD
Olopatadine—Muscle spasms—Cisplatin—esophageal cancer	0.00101	0.00634	CcSEcCtD
Olopatadine—Infestation NOS—Capecitabine—esophageal cancer	0.000988	0.00622	CcSEcCtD
Olopatadine—Infestation—Capecitabine—esophageal cancer	0.000988	0.00622	CcSEcCtD
Olopatadine—Vision blurred—Cisplatin—esophageal cancer	0.000987	0.00621	CcSEcCtD
Olopatadine—Depression—Capecitabine—esophageal cancer	0.000985	0.0062	CcSEcCtD
Olopatadine—Ill-defined disorder—Cisplatin—esophageal cancer	0.000972	0.00612	CcSEcCtD
Olopatadine—Urinary tract infection—Capecitabine—esophageal cancer	0.00096	0.00605	CcSEcCtD
Olopatadine—Conjunctivitis—Capecitabine—esophageal cancer	0.00096	0.00605	CcSEcCtD
Olopatadine—Malaise—Cisplatin—esophageal cancer	0.000945	0.00595	CcSEcCtD
Olopatadine—Epistaxis—Capecitabine—esophageal cancer	0.000932	0.00587	CcSEcCtD
Olopatadine—Rhinitis—Capecitabine—esophageal cancer	0.000889	0.0056	CcSEcCtD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000886	0.00558	CcSEcCtD
Olopatadine—Hypoaesthesia—Capecitabine—esophageal cancer	0.000883	0.00556	CcSEcCtD
Olopatadine—Discomfort—Cisplatin—esophageal cancer	0.000881	0.00555	CcSEcCtD
Olopatadine—Pharyngitis—Capecitabine—esophageal cancer	0.00088	0.00554	CcSEcCtD
Olopatadine—Oedema—Cisplatin—esophageal cancer	0.000855	0.00538	CcSEcCtD
Olopatadine—Visual impairment—Capecitabine—esophageal cancer	0.000855	0.00538	CcSEcCtD
Olopatadine—Infection—Cisplatin—esophageal cancer	0.000849	0.00535	CcSEcCtD
Olopatadine—Nervous system disorder—Cisplatin—esophageal cancer	0.000838	0.00528	CcSEcCtD
Olopatadine—Skin disorder—Cisplatin—esophageal cancer	0.00083	0.00523	CcSEcCtD
Olopatadine—Eye disorder—Capecitabine—esophageal cancer	0.000829	0.00522	CcSEcCtD
Olopatadine—Immune system disorder—Capecitabine—esophageal cancer	0.000801	0.00504	CcSEcCtD
Olopatadine—Mediastinal disorder—Capecitabine—esophageal cancer	0.000799	0.00503	CcSEcCtD
Olopatadine—Erythema—Capecitabine—esophageal cancer	0.000772	0.00486	CcSEcCtD
Olopatadine—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000767	0.00483	CcSEcCtD
Olopatadine—Dyspnoea—Cisplatin—esophageal cancer	0.000762	0.0048	CcSEcCtD
Olopatadine—Dysgeusia—Capecitabine—esophageal cancer	0.000756	0.00476	CcSEcCtD
Olopatadine—Back pain—Capecitabine—esophageal cancer	0.000747	0.0047	CcSEcCtD
Olopatadine—Muscle spasms—Capecitabine—esophageal cancer	0.000742	0.00467	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000738	0.00465	CcSEcCtD
Olopatadine—Infestation NOS—Methotrexate—esophageal cancer	0.000736	0.00463	CcSEcCtD
Olopatadine—Infestation—Methotrexate—esophageal cancer	0.000736	0.00463	CcSEcCtD
Olopatadine—Depression—Methotrexate—esophageal cancer	0.000733	0.00462	CcSEcCtD
Olopatadine—Pain—Cisplatin—esophageal cancer	0.000731	0.0046	CcSEcCtD
Olopatadine—Vision blurred—Capecitabine—esophageal cancer	0.000728	0.00458	CcSEcCtD
Olopatadine—Ill-defined disorder—Capecitabine—esophageal cancer	0.000716	0.00451	CcSEcCtD
Olopatadine—Conjunctivitis—Methotrexate—esophageal cancer	0.000715	0.0045	CcSEcCtD
Olopatadine—Feeling abnormal—Cisplatin—esophageal cancer	0.000704	0.00443	CcSEcCtD
Olopatadine—Malaise—Capecitabine—esophageal cancer	0.000696	0.00438	CcSEcCtD
Olopatadine—Epistaxis—Methotrexate—esophageal cancer	0.000694	0.00437	CcSEcCtD
Olopatadine—Body temperature increased—Cisplatin—esophageal cancer	0.000676	0.00425	CcSEcCtD
Olopatadine—Cough—Capecitabine—esophageal cancer	0.000674	0.00424	CcSEcCtD
Olopatadine—Pharyngitis—Methotrexate—esophageal cancer	0.000655	0.00413	CcSEcCtD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000653	0.00411	CcSEcCtD
Olopatadine—Discomfort—Capecitabine—esophageal cancer	0.000649	0.00409	CcSEcCtD
Olopatadine—Dry mouth—Capecitabine—esophageal cancer	0.000643	0.00405	CcSEcCtD
Olopatadine—Visual impairment—Methotrexate—esophageal cancer	0.000636	0.00401	CcSEcCtD
Olopatadine—Oedema—Capecitabine—esophageal cancer	0.00063	0.00397	CcSEcCtD
Olopatadine—Hypersensitivity—Cisplatin—esophageal cancer	0.00063	0.00397	CcSEcCtD
Olopatadine—Infection—Capecitabine—esophageal cancer	0.000626	0.00394	CcSEcCtD
Olopatadine—Nervous system disorder—Capecitabine—esophageal cancer	0.000618	0.00389	CcSEcCtD
Olopatadine—Eye disorder—Methotrexate—esophageal cancer	0.000617	0.00388	CcSEcCtD
Olopatadine—Asthenia—Cisplatin—esophageal cancer	0.000613	0.00386	CcSEcCtD
Olopatadine—Skin disorder—Capecitabine—esophageal cancer	0.000612	0.00385	CcSEcCtD
Olopatadine—Immune system disorder—Methotrexate—esophageal cancer	0.000596	0.00375	CcSEcCtD
Olopatadine—Mediastinal disorder—Methotrexate—esophageal cancer	0.000595	0.00375	CcSEcCtD
Olopatadine—Diarrhoea—Cisplatin—esophageal cancer	0.000585	0.00368	CcSEcCtD
Olopatadine—Erythema—Methotrexate—esophageal cancer	0.000575	0.00362	CcSEcCtD
Olopatadine—Dysgeusia—Methotrexate—esophageal cancer	0.000563	0.00354	CcSEcCtD
Olopatadine—Dyspnoea—Capecitabine—esophageal cancer	0.000562	0.00354	CcSEcCtD
Olopatadine—Back pain—Methotrexate—esophageal cancer	0.000556	0.0035	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000544	0.00342	CcSEcCtD
Olopatadine—Vomiting—Cisplatin—esophageal cancer	0.000544	0.00342	CcSEcCtD
Olopatadine—Fatigue—Capecitabine—esophageal cancer	0.000543	0.00342	CcSEcCtD
Olopatadine—Vision blurred—Methotrexate—esophageal cancer	0.000542	0.00341	CcSEcCtD
Olopatadine—Rash—Cisplatin—esophageal cancer	0.000539	0.00339	CcSEcCtD
Olopatadine—Pain—Capecitabine—esophageal cancer	0.000539	0.00339	CcSEcCtD
Olopatadine—Dermatitis—Cisplatin—esophageal cancer	0.000539	0.00339	CcSEcCtD
Olopatadine—Ill-defined disorder—Methotrexate—esophageal cancer	0.000533	0.00336	CcSEcCtD
Olopatadine—Feeling abnormal—Capecitabine—esophageal cancer	0.000519	0.00327	CcSEcCtD
Olopatadine—Malaise—Methotrexate—esophageal cancer	0.000518	0.00326	CcSEcCtD
Olopatadine—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000515	0.00324	CcSEcCtD
Olopatadine—Nausea—Cisplatin—esophageal cancer	0.000508	0.0032	CcSEcCtD
Olopatadine—Cough—Methotrexate—esophageal cancer	0.000502	0.00316	CcSEcCtD
Olopatadine—Abdominal pain—Capecitabine—esophageal cancer	0.000498	0.00314	CcSEcCtD
Olopatadine—Body temperature increased—Capecitabine—esophageal cancer	0.000498	0.00314	CcSEcCtD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000486	0.00306	CcSEcCtD
Olopatadine—Discomfort—Methotrexate—esophageal cancer	0.000483	0.00304	CcSEcCtD
Olopatadine—Infection—Methotrexate—esophageal cancer	0.000466	0.00293	CcSEcCtD
Olopatadine—Hypersensitivity—Capecitabine—esophageal cancer	0.000464	0.00292	CcSEcCtD
Olopatadine—Nervous system disorder—Methotrexate—esophageal cancer	0.00046	0.0029	CcSEcCtD
Olopatadine—Skin disorder—Methotrexate—esophageal cancer	0.000456	0.00287	CcSEcCtD
Olopatadine—Asthenia—Capecitabine—esophageal cancer	0.000452	0.00285	CcSEcCtD
Olopatadine—Pruritus—Capecitabine—esophageal cancer	0.000446	0.00281	CcSEcCtD
Olopatadine—Diarrhoea—Capecitabine—esophageal cancer	0.000431	0.00271	CcSEcCtD
Olopatadine—S100A12—Innate Immune System—HMGB1—esophageal cancer	0.000431	0.000851	CbGpPWpGaD
Olopatadine—CYP3A4—Tryptophan metabolism—ALDH2—esophageal cancer	0.000429	0.000848	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—KMT2D—esophageal cancer	0.00042	0.000831	CbGpPWpGaD
Olopatadine—Dyspnoea—Methotrexate—esophageal cancer	0.000418	0.00263	CcSEcCtD
Olopatadine—Somnolence—Methotrexate—esophageal cancer	0.000417	0.00263	CcSEcCtD
Olopatadine—Dizziness—Capecitabine—esophageal cancer	0.000417	0.00262	CcSEcCtD
Olopatadine—S100B—Innate Immune System—HMGB1—esophageal cancer	0.000407	0.000805	CbGpPWpGaD
Olopatadine—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000405	0.00255	CcSEcCtD
Olopatadine—Fatigue—Methotrexate—esophageal cancer	0.000404	0.00255	CcSEcCtD
Olopatadine—S100A12—Immune System—ELMO1—esophageal cancer	0.000404	0.000799	CbGpPWpGaD
Olopatadine—Pain—Methotrexate—esophageal cancer	0.000401	0.00253	CcSEcCtD
Olopatadine—Vomiting—Capecitabine—esophageal cancer	0.000401	0.00252	CcSEcCtD
Olopatadine—CYP3A4—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.000399	0.000789	CbGpPWpGaD
Olopatadine—Rash—Capecitabine—esophageal cancer	0.000397	0.0025	CcSEcCtD
Olopatadine—Dermatitis—Capecitabine—esophageal cancer	0.000397	0.0025	CcSEcCtD
Olopatadine—Headache—Capecitabine—esophageal cancer	0.000395	0.00249	CcSEcCtD
Olopatadine—Feeling abnormal—Methotrexate—esophageal cancer	0.000387	0.00243	CcSEcCtD
Olopatadine—HRH1—G alpha (q) signalling events—GNG7—esophageal cancer	0.000384	0.000759	CbGpPWpGaD
Olopatadine—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000384	0.00241	CcSEcCtD
Olopatadine—S100B—Immune System—ELMO1—esophageal cancer	0.000382	0.000755	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—ADCYAP1—esophageal cancer	0.000375	0.000741	CbGpPWpGaD
Olopatadine—Nausea—Capecitabine—esophageal cancer	0.000374	0.00236	CcSEcCtD
Olopatadine—CYP3A4—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.000371	0.000733	CbGpPWpGaD
Olopatadine—Body temperature increased—Methotrexate—esophageal cancer	0.000371	0.00233	CcSEcCtD
Olopatadine—Abdominal pain—Methotrexate—esophageal cancer	0.000371	0.00233	CcSEcCtD
Olopatadine—S100B—Signaling by ERBB4—EGFR—esophageal cancer	0.000368	0.000727	CbGpPWpGaD
Olopatadine—S100A12—Immune System—CFL1—esophageal cancer	0.000364	0.00072	CbGpPWpGaD
Olopatadine—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—esophageal cancer	0.000358	0.000707	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—ABL1—esophageal cancer	0.000356	0.000704	CbGpPWpGaD
Olopatadine—S100A12—Immune System—LGALS3—esophageal cancer	0.000349	0.00069	CbGpPWpGaD
Olopatadine—Hypersensitivity—Methotrexate—esophageal cancer	0.000346	0.00218	CcSEcCtD
Olopatadine—HRH1—GPCR ligand binding—ADCYAP1—esophageal cancer	0.000345	0.000682	CbGpPWpGaD
Olopatadine—S100B—Immune System—CFL1—esophageal cancer	0.000345	0.000681	CbGpPWpGaD
Olopatadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—GNG7—esophageal cancer	0.000343	0.000678	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—WWOX—esophageal cancer	0.000343	0.000677	CbGpPWpGaD
Olopatadine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.000341	0.000674	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—ABL1—esophageal cancer	0.000337	0.000666	CbGpPWpGaD
Olopatadine—Asthenia—Methotrexate—esophageal cancer	0.000337	0.00212	CcSEcCtD
Olopatadine—Pruritus—Methotrexate—esophageal cancer	0.000332	0.00209	CcSEcCtD
Olopatadine—S100B—Immune System—LGALS3—esophageal cancer	0.00033	0.000653	CbGpPWpGaD
Olopatadine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.000326	0.000644	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—FKBP1A—esophageal cancer	0.000326	0.000644	CbGpPWpGaD
Olopatadine—CYP3A4—Tryptophan metabolism—CYP1B1—esophageal cancer	0.000325	0.000643	CbGpPWpGaD
Olopatadine—CYP3A4—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.000322	0.000636	CbGpPWpGaD
Olopatadine—Diarrhoea—Methotrexate—esophageal cancer	0.000321	0.00202	CcSEcCtD
Olopatadine—S100B—Signaling by ERBB4—PIK3CA—esophageal cancer	0.000319	0.000631	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—WIF1—esophageal cancer	0.000319	0.00063	CbGpPWpGaD
Olopatadine—HRH1—G alpha (q) signalling events—ANXA1—esophageal cancer	0.000314	0.000621	CbGpPWpGaD
Olopatadine—Dizziness—Methotrexate—esophageal cancer	0.00031	0.00195	CcSEcCtD
Olopatadine—S100A12—Immune System—ACTB—esophageal cancer	0.00031	0.000613	CbGpPWpGaD
Olopatadine—CYP3A4—Tryptophan metabolism—CYP19A1—esophageal cancer	0.000306	0.000604	CbGpPWpGaD
Olopatadine—S100A12—Immune System—PTPN2—esophageal cancer	0.000303	0.000598	CbGpPWpGaD
Olopatadine—S100A12—Immune System—B2M—esophageal cancer	0.000299	0.000592	CbGpPWpGaD
Olopatadine—Vomiting—Methotrexate—esophageal cancer	0.000298	0.00188	CcSEcCtD
Olopatadine—HRH1—G alpha (q) signalling events—GHRL—esophageal cancer	0.000298	0.000589	CbGpPWpGaD
Olopatadine—Rash—Methotrexate—esophageal cancer	0.000296	0.00186	CcSEcCtD
Olopatadine—Dermatitis—Methotrexate—esophageal cancer	0.000296	0.00186	CcSEcCtD
Olopatadine—S100B—Signaling Pathways—CSNK1A1—esophageal cancer	0.000294	0.000581	CbGpPWpGaD
Olopatadine—Headache—Methotrexate—esophageal cancer	0.000294	0.00185	CcSEcCtD
Olopatadine—S100B—Immune System—ACTB—esophageal cancer	0.000293	0.000579	CbGpPWpGaD
Olopatadine—S100B—Immune System—PTPN2—esophageal cancer	0.000286	0.000566	CbGpPWpGaD
Olopatadine—S100B—Immune System—B2M—esophageal cancer	0.000283	0.000559	CbGpPWpGaD
Olopatadine—S100A12—Immune System—PSME2—esophageal cancer	0.000283	0.000559	CbGpPWpGaD
Olopatadine—S100A12—Immune System—PSME1—esophageal cancer	0.000283	0.000559	CbGpPWpGaD
Olopatadine—CYP3A4—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.000281	0.000556	CbGpPWpGaD
Olopatadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—ANXA1—esophageal cancer	0.000281	0.000556	CbGpPWpGaD
Olopatadine—S100A12—Immune System—HSPA5—esophageal cancer	0.00028	0.000554	CbGpPWpGaD
Olopatadine—Nausea—Methotrexate—esophageal cancer	0.000279	0.00175	CcSEcCtD
Olopatadine—HRH1—IL-4 Signaling Pathway—EP300—esophageal cancer	0.000276	0.000545	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—PFN1—esophageal cancer	0.000275	0.000544	CbGpPWpGaD
Olopatadine—S100A12—Immune System—CALR—esophageal cancer	0.000271	0.000536	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—TLR4—esophageal cancer	0.00027	0.000534	CbGpPWpGaD
Olopatadine—S100B—Immune System—PSME2—esophageal cancer	0.000267	0.000529	CbGpPWpGaD
Olopatadine—S100B—Immune System—PSME1—esophageal cancer	0.000267	0.000529	CbGpPWpGaD
Olopatadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—GHRL—esophageal cancer	0.000266	0.000527	CbGpPWpGaD
Olopatadine—S100B—Immune System—HSPA5—esophageal cancer	0.000265	0.000524	CbGpPWpGaD
Olopatadine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000264	0.000522	CbGpPWpGaD
Olopatadine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.000263	0.000519	CbGpPWpGaD
Olopatadine—S100A12—Immune System—FBXW7—esophageal cancer	0.000262	0.000519	CbGpPWpGaD
Olopatadine—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.000259	0.000513	CbGpPWpGaD
Olopatadine—S100B—Immune System—CALR—esophageal cancer	0.000257	0.000507	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—TLR4—esophageal cancer	0.000255	0.000505	CbGpPWpGaD
Olopatadine—Nortriptyline—PTGS1—esophageal cancer	0.000253	0.322	CrCbGaD
Olopatadine—S100A12—Immune System—HMGB1—esophageal cancer	0.000251	0.000496	CbGpPWpGaD
Olopatadine—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.000251	0.000495	CbGpPWpGaD
Olopatadine—S100B—Immune System—FBXW7—esophageal cancer	0.000248	0.000491	CbGpPWpGaD
Olopatadine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000247	0.000488	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—ELMO1—esophageal cancer	0.000247	0.000488	CbGpPWpGaD
Olopatadine—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000244	0.000482	CbGpPWpGaD
Olopatadine—CYP3A4—Biological oxidations—ADH7—esophageal cancer	0.000242	0.000478	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—AKAP13—esophageal cancer	0.000241	0.000477	CbGpPWpGaD
Olopatadine—S100B—Immune System—HMGB1—esophageal cancer	0.000237	0.000469	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—CASP8—esophageal cancer	0.000232	0.000458	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—CREBBP—esophageal cancer	0.000231	0.000456	CbGpPWpGaD
Olopatadine—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCL2—esophageal cancer	0.000224	0.000443	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000223	0.000441	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—PDE4D—esophageal cancer	0.000221	0.000437	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—CASP8—esophageal cancer	0.000219	0.000433	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—CREBBP—esophageal cancer	0.000218	0.000431	CbGpPWpGaD
Olopatadine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000213	0.000421	CbGpPWpGaD
Olopatadine—CYP3A4—Biological oxidations—ADH1B—esophageal cancer	0.000212	0.000419	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—GNG7—esophageal cancer	0.00021	0.000415	CbGpPWpGaD
Olopatadine—HRH1—Class A/1 (Rhodopsin-like receptors)—ANXA1—esophageal cancer	0.000208	0.000411	CbGpPWpGaD
Olopatadine—S100A12—Immune System—ABL1—esophageal cancer	0.000207	0.00041	CbGpPWpGaD
Olopatadine—HRH1—IL-4 Signaling Pathway—PIK3CA—esophageal cancer	0.000204	0.000403	CbGpPWpGaD
Olopatadine—HRH1—Class A/1 (Rhodopsin-like receptors)—SST—esophageal cancer	0.000202	0.0004	CbGpPWpGaD
Olopatadine—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.0002	0.000396	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—BCL2—esophageal cancer	0.000199	0.000393	CbGpPWpGaD
Olopatadine—HRH1—Class A/1 (Rhodopsin-like receptors)—GHRL—esophageal cancer	0.000197	0.00039	CbGpPWpGaD
Olopatadine—CYP3A4—Biological oxidations—CYP26A1—esophageal cancer	0.000197	0.000389	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—XIAP—esophageal cancer	0.000197	0.000389	CbGpPWpGaD
Olopatadine—S100B—Immune System—ABL1—esophageal cancer	0.000196	0.000388	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—ADCYAP1—esophageal cancer	0.000195	0.000386	CbGpPWpGaD
Olopatadine—CYP3A4—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000194	0.000384	CbGpPWpGaD
Olopatadine—HRH1—GPCR ligand binding—GNG7—esophageal cancer	0.000193	0.000383	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—ERBB2—esophageal cancer	0.000193	0.000382	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—BCL2—esophageal cancer	0.000188	0.000372	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—CTNNA1—esophageal cancer	0.000186	0.000368	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—CXCL2—esophageal cancer	0.000185	0.000366	CbGpPWpGaD
Olopatadine—CYP3A4—Biological oxidations—GSTO1—esophageal cancer	0.000183	0.000362	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—ERBB2—esophageal cancer	0.000183	0.000361	CbGpPWpGaD
Olopatadine—CYP3A4—Metapathway biotransformation—GSTO1—esophageal cancer	0.000181	0.000357	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—ADCYAP1—esophageal cancer	0.000177	0.00035	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—PSME2—esophageal cancer	0.000173	0.000342	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—PSME1—esophageal cancer	0.000173	0.000342	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—ANXA1—esophageal cancer	0.000172	0.00034	CbGpPWpGaD
Olopatadine—HRH1—GPCR ligand binding—CXCL2—esophageal cancer	0.00017	0.000337	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—SST—esophageal cancer	0.000167	0.000331	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—CDKN1A—esophageal cancer	0.000165	0.000326	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—GHRL—esophageal cancer	0.000163	0.000322	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—NOTCH3—esophageal cancer	0.000163	0.000322	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—GDI2—esophageal cancer	0.000162	0.000321	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—FBXW7—esophageal cancer	0.00016	0.000317	CbGpPWpGaD
Olopatadine—HRH1—GPCR ligand binding—ANXA1—esophageal cancer	0.000158	0.000313	CbGpPWpGaD
Olopatadine—S100A12—Immune System—TLR4—esophageal cancer	0.000157	0.000311	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—EP300—esophageal cancer	0.000157	0.00031	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—CDKN1A—esophageal cancer	0.000156	0.000308	CbGpPWpGaD
Olopatadine—HRH1—GPCR ligand binding—SST—esophageal cancer	0.000154	0.000305	CbGpPWpGaD
Olopatadine—HRH1—GPCR ligand binding—GHRL—esophageal cancer	0.00015	0.000297	CbGpPWpGaD
Olopatadine—CYP3A4—Biological oxidations—ALDH2—esophageal cancer	0.000149	0.000295	CbGpPWpGaD
Olopatadine—S100B—Immune System—TLR4—esophageal cancer	0.000149	0.000294	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—EP300—esophageal cancer	0.000148	0.000294	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—NOTCH2—esophageal cancer	0.000146	0.000289	CbGpPWpGaD
Olopatadine—CYP3A4—Biological oxidations—GSTT1—esophageal cancer	0.000142	0.000281	CbGpPWpGaD
Olopatadine—CYP3A4—Biological oxidations—CYP2A6—esophageal cancer	0.00014	0.000278	CbGpPWpGaD
Olopatadine—S100A12—Immune System—CASP8—esophageal cancer	0.000135	0.000267	CbGpPWpGaD
Olopatadine—S100A12—Immune System—CREBBP—esophageal cancer	0.000134	0.000265	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—EGFR—esophageal cancer	0.000134	0.000265	CbGpPWpGaD
Olopatadine—CYP3A4—Biological oxidations—PTGS1—esophageal cancer	0.000133	0.000263	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—TGFBR2—esophageal cancer	0.00013	0.000257	CbGpPWpGaD
Olopatadine—S100B—Immune System—CASP8—esophageal cancer	0.000128	0.000252	CbGpPWpGaD
Olopatadine—S100B—Immune System—CREBBP—esophageal cancer	0.000127	0.000251	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—EGFR—esophageal cancer	0.000127	0.00025	CbGpPWpGaD
Olopatadine—Clomipramine—ABCB1—esophageal cancer	0.000126	0.16	CrCbGaD
Olopatadine—HRH1—GPCR downstream signaling—AKAP13—esophageal cancer	0.000126	0.000248	CbGpPWpGaD
Olopatadine—Chlorprothixene—ABCB1—esophageal cancer	0.000125	0.159	CrCbGaD
Olopatadine—S100B—Signaling Pathways—SMAD4—esophageal cancer	0.000123	0.000243	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—KMT2D—esophageal cancer	0.000117	0.000232	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—PIK3CA—esophageal cancer	0.000116	0.00023	CbGpPWpGaD
Olopatadine—S100A12—Immune System—BCL2—esophageal cancer	0.000116	0.000229	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—PDE4D—esophageal cancer	0.000115	0.000227	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—AKAP13—esophageal cancer	0.000114	0.000226	CbGpPWpGaD
Olopatadine—CYP3A4—Biological oxidations—CYP1B1—esophageal cancer	0.000113	0.000224	CbGpPWpGaD
Olopatadine—S100A12—Immune System—ERBB2—esophageal cancer	0.000112	0.000222	CbGpPWpGaD
Olopatadine—CYP3A4—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000112	0.000221	CbGpPWpGaD
Olopatadine—Doxepin—ABCB1—esophageal cancer	0.00011	0.14	CrCbGaD
Olopatadine—S100B—Innate Immune System—PIK3CA—esophageal cancer	0.00011	0.000217	CbGpPWpGaD
Olopatadine—S100B—Immune System—BCL2—esophageal cancer	0.000109	0.000216	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—GNG7—esophageal cancer	0.000109	0.000216	CbGpPWpGaD
Olopatadine—CYP3A4—Biological oxidations—CYP19A1—esophageal cancer	0.000106	0.00021	CbGpPWpGaD
Olopatadine—S100B—Immune System—ERBB2—esophageal cancer	0.000106	0.00021	CbGpPWpGaD
Olopatadine—CYP3A4—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000105	0.000207	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—ADCYAP1—esophageal cancer	0.000105	0.000207	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—PDE4D—esophageal cancer	0.000104	0.000206	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—HIF1A—esophageal cancer	0.0001	0.000199	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—GNG7—esophageal cancer	9.93e-05	0.000196	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—CXCL2—esophageal cancer	9.63e-05	0.00019	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—KDR—esophageal cancer	9.61e-05	0.00019	CbGpPWpGaD
Olopatadine—S100A12—Immune System—CDKN1A—esophageal cancer	9.61e-05	0.00019	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—WWOX—esophageal cancer	9.57e-05	0.000189	CbGpPWpGaD
Olopatadine—S100A12—Immune System—EP300—esophageal cancer	9.14e-05	0.000181	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—FKBP1A—esophageal cancer	9.1e-05	0.00018	CbGpPWpGaD
Olopatadine—S100B—Immune System—CDKN1A—esophageal cancer	9.09e-05	0.00018	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—NOTCH1—esophageal cancer	9.05e-05	0.000179	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—ANXA1—esophageal cancer	8.96e-05	0.000177	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—WIF1—esophageal cancer	8.9e-05	0.000176	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—CXCL2—esophageal cancer	8.75e-05	0.000173	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—SST—esophageal cancer	8.71e-05	0.000172	CbGpPWpGaD
Olopatadine—S100B—Immune System—EP300—esophageal cancer	8.65e-05	0.000171	CbGpPWpGaD
Olopatadine—Imipramine—ABCB1—esophageal cancer	8.58e-05	0.109	CrCbGaD
Olopatadine—Amitriptyline—ABCB1—esophageal cancer	8.53e-05	0.109	CrCbGaD
Olopatadine—HRH1—GPCR downstream signaling—GHRL—esophageal cancer	8.49e-05	0.000168	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CSNK1A1—esophageal cancer	8.21e-05	0.000162	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—CREBBP—esophageal cancer	8.21e-05	0.000162	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—ANXA1—esophageal cancer	8.13e-05	0.000161	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—SST—esophageal cancer	7.91e-05	0.000156	CbGpPWpGaD
Olopatadine—S100A12—Immune System—EGFR—esophageal cancer	7.79e-05	0.000154	CbGpPWpGaD
Olopatadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—esophageal cancer	7.78e-05	0.000154	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—GHRL—esophageal cancer	7.71e-05	0.000152	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PFN1—esophageal cancer	7.68e-05	0.000152	CbGpPWpGaD
Olopatadine—HRH1—G alpha (q) signalling events—PIK3CA—esophageal cancer	7.55e-05	0.000149	CbGpPWpGaD
Olopatadine—S100B—Immune System—EGFR—esophageal cancer	7.37e-05	0.000146	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—NOS3—esophageal cancer	7.35e-05	0.000145	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—ELMO1—esophageal cancer	6.9e-05	0.000136	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—ERBB2—esophageal cancer	6.87e-05	0.000136	CbGpPWpGaD
Olopatadine—S100A12—Immune System—PIK3CA—esophageal cancer	6.76e-05	0.000134	CbGpPWpGaD
Olopatadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—esophageal cancer	6.76e-05	0.000134	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—AKAP13—esophageal cancer	6.74e-05	0.000133	CbGpPWpGaD
Olopatadine—S100B—Immune System—PIK3CA—esophageal cancer	6.4e-05	0.000126	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—HIST1H2BM—esophageal cancer	6.22e-05	0.000123	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PDE4D—esophageal cancer	6.17e-05	0.000122	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—CCND1—esophageal cancer	6.07e-05	0.00012	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—CDKN1A—esophageal cancer	5.88e-05	0.000116	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—GNG7—esophageal cancer	5.87e-05	0.000116	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—SLC52A3—esophageal cancer	5.72e-05	0.000113	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—BLVRB—esophageal cancer	5.72e-05	0.000113	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—EP300—esophageal cancer	5.59e-05	0.000111	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—XIAP—esophageal cancer	5.5e-05	0.000109	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CTNNA1—esophageal cancer	5.2e-05	0.000103	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CXCL2—esophageal cancer	5.17e-05	0.000102	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—MYC—esophageal cancer	4.87e-05	9.63e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—SLC10A2—esophageal cancer	4.86e-05	9.61e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CA1—esophageal cancer	4.86e-05	9.61e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PSME1—esophageal cancer	4.83e-05	9.54e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PSME2—esophageal cancer	4.83e-05	9.54e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—ANXA1—esophageal cancer	4.8e-05	9.5e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—EGFR—esophageal cancer	4.76e-05	9.42e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—SST—esophageal cancer	4.67e-05	9.24e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—NOTCH3—esophageal cancer	4.55e-05	9e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—GHRL—esophageal cancer	4.55e-05	9e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—FBXW7—esophageal cancer	4.48e-05	8.86e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CA2—esophageal cancer	4.45e-05	8.79e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—PIK3CA—esophageal cancer	4.14e-05	8.18e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—ADH7—esophageal cancer	4.13e-05	8.17e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PLCE1—esophageal cancer	4.13e-05	8.17e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—NOTCH2—esophageal cancer	4.08e-05	8.08e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—TP53—esophageal cancer	4e-05	7.91e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—ADH1B—esophageal cancer	3.62e-05	7.16e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—TGFBR2—esophageal cancer	3.62e-05	7.16e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—TYMP—esophageal cancer	3.46e-05	6.85e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—SMAD4—esophageal cancer	3.43e-05	6.78e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CYP26A1—esophageal cancer	3.37e-05	6.66e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—ALOX15—esophageal cancer	3.28e-05	6.49e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—TPI1—esophageal cancer	3.13e-05	6.19e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—GSTO1—esophageal cancer	3.13e-05	6.19e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—ALDOB—esophageal cancer	3e-05	5.94e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—GAPDH—esophageal cancer	2.89e-05	5.71e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CRABP1—esophageal cancer	2.86e-05	5.66e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—HIF1A—esophageal cancer	2.81e-05	5.55e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—GNG7—esophageal cancer	2.72e-05	5.39e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—KDR—esophageal cancer	2.68e-05	5.31e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—ALDH2—esophageal cancer	2.55e-05	5.05e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—NOTCH1—esophageal cancer	2.53e-05	5e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—GSTT1—esophageal cancer	2.43e-05	4.8e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CYP2A6—esophageal cancer	2.4e-05	4.75e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CREBBP—esophageal cancer	2.29e-05	4.53e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—ENO1—esophageal cancer	2.28e-05	4.5e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PTGS1—esophageal cancer	2.28e-05	4.5e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—EGFR—esophageal cancer	2.25e-05	4.45e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PSME2—esophageal cancer	2.24e-05	4.43e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PSME1—esophageal cancer	2.24e-05	4.43e-05	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—PIK3CA—esophageal cancer	2.15e-05	4.26e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—NOS3—esophageal cancer	2.05e-05	4.06e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—PIK3CA—esophageal cancer	1.96e-05	3.87e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CYP1B1—esophageal cancer	1.93e-05	3.83e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—ERBB2—esophageal cancer	1.92e-05	3.8e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CYP19A1—esophageal cancer	1.82e-05	3.6e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CCND1—esophageal cancer	1.7e-05	3.35e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—HMOX1—esophageal cancer	1.66e-05	3.28e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CDKN1A—esophageal cancer	1.64e-05	3.24e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—ABCB1—esophageal cancer	1.59e-05	3.15e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—EP300—esophageal cancer	1.56e-05	3.09e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—MYC—esophageal cancer	1.36e-05	2.69e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—EGFR—esophageal cancer	1.33e-05	2.63e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PIK3CA—esophageal cancer	1.15e-05	2.28e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—TP53—esophageal cancer	1.12e-05	2.21e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CREBBP—esophageal cancer	1.06e-05	2.11e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—NOS3—esophageal cancer	9.53e-06	1.89e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PTGS2—esophageal cancer	8.72e-06	1.72e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—EP300—esophageal cancer	7.25e-06	1.43e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PIK3CA—esophageal cancer	5.37e-06	1.06e-05	CbGpPWpGaD
